Skip to content
stoqly

BioLife Solutions

BLFS Nasdaq Health Care Supplies Financials FY2016–FY2025

BioLife Solutions' revenue rose 28.9% to $96 million in fiscal 2025. Its operating margin was −17.3%, down from −6.0% a year earlier. Free cash flow was $11 million, up 104.4%. The diluted share count rose 5.6%.

Revenue Total sales reported in the income statement.
$96.2M
29.0% vs prior year
Operating margin Operating income as a share of revenue.
−17.3%
11.3 pts
Net income Profit after all expenses, interest and tax.
−$4.6M
Free cash flow Cash from operations minus capital spending.
$10.6M
104.6%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
−4.8%
3.5 pts
Market cap Last close times the latest diluted share count, so it is approximate.
—
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On $1.17 EPS (TTM)

About these figures. BioLife Solutions' operating loss in 2025 leaves its earnings before interest, tax, depreciation and amortization negative, so net debt to EBITDA is blank for that year.

What BioLife Solutions does

No business description yet.

Legal name
BioLife Solutions, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
—
Accession · CIK
0001628280-26-012294
0000834365

Revenue and margins

BioLife Solutions had $96.2M of revenue in fiscal 2025, up 28.9% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $10.6M in fiscal 2025, 11.1% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

BioLife Solutions returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 5.6%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value BioLife Solutions yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of $83.9M and divides by 48.6M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today — · peers 49.0x · sector 28.1x.

Balance sheet

Cash, debt and the ratios that show how comfortably BioLife Solutions can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $69.9M$62.7M$44.2M$101M$88.9M
Debt incl. finance leases $7.7M$25.9M$25.4M$15.9M$5.0M
Net debt / EBITDA —−43.2x—−124.2x—
Debt / equity 0.0x0.1x0.1x0.1x0.0x
Interest coverage −77.8x−10.1x−8.9x−2.8x−21.8x
Current ratio 3.0x3.1x2.9x4.5x5.9x
Quick ratio 2.3x2.3x2.2x3.7x4.6x
Total assets $554M$450M$413M$400M$406M
Total liabilities $76.2M$86.0M$75.1M$50.6M$34.0M
Shareholders' equity $478M$364M$338M$349M$372M
Net debt (− = net cash) −$62.2M−$36.8M−$18.8M−$84.8M−$83.9M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$30.2M

7 insiders

Of sales under plans

0%

$0.1M

DateInsiderTradeSharesPriceValueFiling
May 21, 2026 Casdin Partners Master Fund L.P.10% owner Sold 650,000 $23.70 $15.4M Form 4
May 20, 2026 Casdin Partners Master Fund L.P.10% owner Sold 250,000 $23.70 $5.9M Form 4
May 19, 2026 Casdin Partners Master Fund L.P.10% owner Sold 300,000 $22.65 $6.8M Form 4
Mar 23, 2026 Karen A. FosterChief Quality and Operations Sold plan 2,577 $19.17 $0.0M Form 4
Mar 9, 2026 Karen A. FosterChief Quality and Operations Sold 500 $20.00 $0.0M Form 4
Mar 5, 2026 Karen A. FosterChief Quality and Operations Sold 96,923 $20.15 $2.0M Form 4
Mar 3, 2026 Aby J. MathewEVP & Chief Scientific Officer Sold plan 529 $20.74 $0.0M Form 4
Mar 3, 2026 Karen A. FosterChief Quality and Operations Sold plan 418 $20.74 $0.0M Form 4
Mar 3, 2026 Sarah AebersoldChief Human Resources Officer Sold plan 219 $20.74 $0.0M Form 4
Mar 3, 2026 Sean WernerChief Technology Officer Sold plan 111 $20.74 $0.0M Form 4
Mar 3, 2026 Todd BerardChief Marketing Officer Sold plan 353 $20.74 $0.0M Form 4
Mar 3, 2026 Troy WichtermanChief Financial Officer Sold plan 588 $20.74 $0.0M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✕ ✕ ✕
Cash from operations is positive ✕ ✓ ✓
Return on assets rose ✓ ✓ ✓
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets ✕ ✓ ✓
Current ratio rose ✕ ✓ ✓
Share count didn't rise ✕ ✕ ✕
Gross margin rose — ✓ ✕
Revenue rose relative to assets ✓ ✓ ✓
F-score 3 / 87 / 96 / 9
Accruals ratio −12.9%−7.1%−6.1%
Altman Z'' 3.206.3410.32

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
BioLife Solutions BLFS — 28.9% −17.3% 11.1% −4.8% — 6
Haemonetics HAE $5.4B −2.0% 11.8% 19.5% 6.7% 57.3x 7 Compare →
Lantheus LNTH $6.7B 0.5% 20.2% 23.0% 22.7% 24.2x 5 Compare →
ICU Medical ICUI $4.2B −6.3% 1.9% 4.1% 0.7% 140.0x 6 Compare →
Envista NVST $3.9B 8.3% 8.0% 8.5% 3.2% 40.7x 7 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $8.2M $11.0M $19.7M $27.4M $48.1M $119M $76.2M $68.0M $74.6M $96.2M
Gross profit $4.8M $6.7M $13.5M $18.6M — — — $41.3M $50.1M $62.1M
Research and development $2.0M $1.2M $1.3M $3.2M $6.7M $11.8M $8.7M $5.5M $4.8M $7.6M
Operating income −$4.9M −$1.1M $3.7M −$0.2M −$6.2M −$35.2M −$5.9M −$17.2M −$4.5M −$16.6M
Interest expense $0.1M $0.2M $0.0M $0.0M $0.0M $0.5M $0.6M $1.9M $1.6M $0.8M
Pretax income −$6.9M −$2.5M −$25.0M −$3.2M −$1.3M −$29.0M −$4.8M −$12.2M −$8.8M −$12.1M
Income tax $0.0M $0.0M — −$1.5M −$3.3M −$20.1M −$5.2M −$0.1M $0.0M $0.0M
Net income −$6.9M −$2.5M −$25.0M −$1.7M $2.0M −$8.9M −$140M −$68.0M −$20.2M −$4.6M
Diluted EPS −$0.54 −$0.21 −$1.56 −$0.09 −$0.06 −$0.23 −$3.25 −$1.55 −$0.44 −$0.10
Diluted shares 0.01B 0.01B 0.02B 0.02B 0.03B 0.04B 0.04B 0.04B 0.05B 0.05B
Cash flow
Cash from operations −$4.3M $0.6M $2.3M $1.2M $6.6M −$4.6M −$8.5M −$12.5M $8.4M $20.1M
Capital expenditure $0.1M $0.1M $0.5M $0.7M $2.0M $8.4M $10.4M $6.4M $3.2M $9.5M
Free cash flow −$4.5M $0.5M $1.9M $0.5M $4.7M −$13.0M −$18.9M −$18.9M $5.2M $10.6M
Depreciation and amortization $0.4M $0.3M $0.3M $0.7M $2.0M $4.7M $6.8M $7.1M $5.2M $2.3M
Stock-based compensation $0.8M $1.3M $1.5M $3.0M $6.0M $14.0M $25.3M $33.2M $30.9M $23.0M
Acquisitions $0.0M $0.0M $0.0M $0.0M $14.9M $0.0M $0.0M $0.0M $0.0M $0.0M
Share buybacks $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends paid $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends and buybacks $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Balance sheet
Cash and short-term investments $1.4M $6.7M $30.7M $6.4M $90.4M $69.9M $62.7M $44.2M $101M $88.9M
Total debt $4.2M — — $0.0M $1.3M $7.2M $25.6M $23.8M $15.9M $5.0M
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $0.0M $0.4M $0.3M $1.5M $0.0M $0.0M
Current assets $4.6M $9.9M $37.6M $24.1M $115M $126M $139M $121M $149M $137M
Current liabilities $1.1M $1.5M $1.9M $7.7M $15.6M $42.7M $44.6M $42.2M $32.7M $23.0M
Inventory $1.8M $1.8M $3.5M $11.0M $11.6M $28.3M $34.9M $27.2M $29.0M $30.2M
Property and equipment, net $1.2M $1.1M $1.3M $5.6M $10.1M $17.7M $23.6M $5.7M $6.0M $14.7M
Total assets $7.9M $12.1M $45.5M $92.8M $235M $554M $450M $413M $400M $406M
Total liabilities $4.8M $2.1M $30.8M $49.4M $29.6M $76.2M $86.0M $75.1M $50.6M $34.0M
Shareholders' equity $3.2M −$9.5M $14.6M $43.3M $204M $478M $364M $338M $349M $372M
Margins
Gross margin 58.1% 61.2% 68.5% 68.0% — — — 60.8% 67.1% 64.6%
Operating margin −59.0% −9.6% 18.6% −0.8% −13.0% −29.5% −7.8% −25.3% −6.0% −17.3%
EBITDA margin −54.5% −6.5% 20.3% 1.8% −8.8% −25.6% 1.1% −14.8% 0.9% −14.9%
Net margin −83.6% −22.8% −126.7% −6.1% 4.1% −7.5% −183.4% −100.0% −27.0% −4.8%
FCF margin −54.3% 4.2% 9.4% 2.0% 9.7% −10.9% −24.8% −27.8% 7.0% 11.1%
Returns
Return on capital — — — — −6.5% −10.5% −1.3% −4.2% −1.2% −4.8%
Return on capital employed −55.7% −12.1% 13.5% −0.3% −4.1% −9.6% −1.3% −4.4% −1.2% −4.4%
Return on equity −117.8% — −980.6% −5.7% 1.6% −2.6% −33.2% −19.4% −5.9% −1.3%
Return on assets −67.8% −25.1% −86.8% −2.4% 1.2% −2.3% −27.8% −15.8% −5.0% −1.1%
Growth
Revenue growth 27.6% 34.0% 79.1% 38.6% 75.7% 147.8% −36.0% −10.8% 9.8% 28.9%
Net income growth — — — — — −549.2% — — — —
FCF growth — — 300.9% −70.9% 770.6% −377.1% — — — 104.4%
Share count change 3.8% 4.9% 63.1% −10.0% 40.3% 41.0% 11.9% 1.5% 5.4% 5.6%
Financial health
Net debt / EBITDA — — — −12.9x — — −43.2x — −124.2x —
Debt / equity 1.3x — — 0.0x 0.0x 0.0x 0.1x 0.1x 0.1x 0.0x
Interest coverage −48.5x −5.6x 732.4x −44.0x — −77.8x −10.1x −8.9x −2.8x −21.8x
Current ratio 4.1x 6.6x 19.4x 3.1x 7.4x 3.0x 3.1x 2.9x 4.5x 5.9x
Quick ratio 2.5x 5.3x 17.6x 1.7x 6.6x 2.3x 2.3x 2.2x 3.7x 4.6x
Capital allocation
Capex / revenue 1.7% 1.3% 2.5% 2.5% 4.1% 7.0% 13.6% 9.4% 4.3% 9.9%
Stock comp / revenue 9.4% 11.5% 7.7% 11.1% 12.4% 11.7% 33.2% 48.9% 41.4% 23.9%
Payouts / FCF — 0.0% 0.0% 0.0% 0.0% — — — 0.0% 0.0%
Quality scores
Piotroski F-score — — — — 5.0 1.0 2.0 3.0 7.0 6.0
Altman Z'' −29.8 −10.7 −0.9 5.6 8.5 6.5 3.9 3.2 6.3 10.3
Accruals ratio −25.1% −31.1% −95.0% −4.2% −2.9% −1.1% −26.2% −12.9% −7.1% −6.1%

Source: SEC EDGAR XBRL filings (CIK 0000834365). Data updated October 22, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open